BioRestorative Therapies (NASDAQ: BRTX) Reports Positive Phase 2 Data for BRTX-100 in Lumbar Disc Disease
Market Overview The healthcare sector saw renewed focus on regenerative medicine as BioRestorative Therapies (NASDAQ: BRTX) released its latest clinical data. The company’s shares attracted investor interest following the announcement of positive Phase 2 results for its key candidate, BRTX-100, targeting chronic lumbar disc disease. This market segment remains a critical area due to the high prevalence of chronic pain conditions and limited effective treatments. BioRestorative Therapies (NASDAQ: BRTX) demonstrated…
